The FDA Peptide Vote Is In: What 6-of-7 Means for Your Stack
The vote you have been waiting on since 2023 is in. Over two days in July — the 23rd and 24th — the FDA's compounding advisory committee reviewed seven peptides and recommended six of them for the legal compounding list. BPC-157. TB-500. KPV. MOTS-c. Semax. Epitalon. All through. The only casualty: DSIP, rejected by a single vote.
Before you celebrate, read the next line twice: nothing is legal yet. Now let's break down what actually happened and what it means for how you train, recover, and source.
The Scoreboard
| Compound | Vote | Why You Care |
|---|---|---|
| BPC-157 | 8–6, 1 abstention | Tendon, ligament, gut — the recovery workhorse |
| TB-500 | 8–6, 1 abstention | Connective tissue, the other half of the Wolverine stack |
| KPV | 8–6, 1 abstention | Inflammation control |
| MOTS-c | 7–5, 2 abstentions | Mitochondrial output, endurance, metabolic health |
| Semax | 8–5, 1 abstention* | Focus and drive |
| Epitalon | 7–5, 1 abstention* | The longevity play |
| DSIP | 6–7 — REJECTED | Deep sleep — the one that didn't make it |
*Day-2 tallies as reported from the live webcast, pending the official transcript.
What Actually Happened in That Room
The FDA's own scientists told the committee to reject all seven. Every briefing document said the same thing: studies too small, too short, and nobody can even agree on the exact chemistry of what's being sold. The 14-member panel overrode them six times in two days. That basically never happens.
The winning argument was not "these work." It was "people are using them anyway." Since the 2023 crackdown, demand went underground — research vials, overseas suppliers, a literal bodega in Queens that came up in testimony. The majority decided a licensed pharmacist with a prescription beats that, even on thin evidence. Harm reduction, not endorsement. The dissenters warned everyone would read the vote as an endorsement anyway. They were right — check your feed.
The Part Nobody Puts in the Headline
A committee recommendation is not a rule. The FDA now has to run formal rulemaking — proposed rule, public comments, final rule — before a single pharmacy can legally compound any of these. Realistic timeline: 12–24 months, into 2027 minimum. And the precedent is ugly: glutathione cleared this same panel in 2022 by a similar margin and still is not on the list four years later. The codified list today holds exactly six substances, five of them topical-only.
What Changes for You Today
- Sourcing: unchanged. Research-grade supply is the same market it was in June, with the same burden on you to verify COAs and third-party testing.
- Legality: unchanged. No pharmacy can compound these. Anyone claiming otherwise is selling something.
- Testing status: unchanged. BPC-157 and TB-500 are still banned by anti-doping authorities. Tested athletes, this vote changes nothing for you.
- Trajectory: changed. For the first time since 2023, the regulatory direction points toward access instead of away from it. That is real, even if the speed is not.
The Smart Play
Watch one signal: a proposed rule in the Federal Register. Until that document exists, nothing is in motion no matter what your feed says. We break down each compound's vote in dedicated pieces — start with the BPC-157 breakdown and the TB-500 story. For the deep science, PeptideOnline has the full regulatory file. If you would rather go the prescribed route with what is already legal, Veritide ranks the licensed telehealth providers.
Partner links. Research compounds are for laboratory use only.
Questions
Six of seven: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. DSIP (emideltide) was rejected by one vote. All votes were narrow and non-binding.
No. The vote was advisory. The FDA must complete formal rulemaking - realistically 12 to 24 months - before any of these can be legally compounded.
Yes. Both remain prohibited by international anti-doping authorities regardless of the compounding vote.
No. FDA scientists recommended against all seven, citing insufficient evidence. The committee's majority voted on harm-reduction grounds, not efficacy.
A proposed rule in the Federal Register. That is the only signal that the legal process has actually started.